Global Diverticulitis Disease Market Overview 2033 : Forecasted Market Size And Growth Rate | Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG

"The new report published by The Business Research Company, titled Diverticulitis Disease Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the diverticulitis disease market size has grown rapidly in recent years. It will grow from $1.68 billion in 2023 to $1.85 billion in 2024 at a compound annual growth rate (CAGR) of 10.4%. The diverticulitis disease market size is expected to see strong growth in the next few years. It will grow to $2.65 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

Increasing Demand For Diverticulitis Treatments Driven By Rising Digestive Disorders
Rising demand for drugs and treatments for digestive disorders is expected to propel the growth of the diverticulitis disease market going forward. Digestive disorders refer to a wide range of conditions that affect the digestive system, which is responsible for breaking down and absorbing nutrients from food. Digestive disorders, such as colorectal cancer, can increase the risk of diverticulitis by contributing to the formation of diverticula and promoting bacterial stagnation in the colon's pouches. For instance, in September 2022, according to the International Agency for Research on Cancer, a France-based government agency, it was estimated that by 2040, there would be 3.2 million new cases and 1.6 million deaths attributed to colorectal cancer each year, representing a significant increase from 1.9 million newly diagnosed patients and 930,000 deaths in 2020. Therefore, the rising demand for drugs and treatments for digestive disorders is driving the growth of the diverticulitis disease market.

Innovative Drug Development Spurs Advances In Diverticulitis Treatments
Major companies operating in the diverticulitis disease market are developing innovative drugs and getting them approved to sustain their position in the market. Drug development can lead to the development of more effective treatments for diverticulitis, reducing the risk of complications and improving patient outcomes. For instance, in April 2023, the United States Food and Drug Administration, a US-based federal organization, approved Seres' microbiota drug for recurrent gut infections. This drug is designed to treat recurring gut infections and prevent the recurrence of Clostridioides difficile (C. diff.) infections in adults aged 18 and over. The approval of Vowst was based on a clinical trial that enrolled 346 patients with recurrent CDI. The trial found that patients who received Vowst were significantly less likely to experience a recurrence of the infection than those who received a placebo. The drug is taken orally and is based on microbiota containing Firmicutes spores, which are known to contribute to a healthy microbiome that can resist C. diff. colonization.

The diverticulitis disease market covered in this report is segmented -

1) By Type: Uncomplicated; Complicated
2) By Diagnosis: Computed Tomography (CT) Scan; Ultrasound; Urine Test; Blood Test
3) By Treatment: Medications; Surgery; Supportive care; Penicillin Antibiotic; Antibiotics; Dietary Supplements; Intravenous (IV) Fluids
4) By End-User: Specialty Centers; Hospitals; Research centers

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12990&type=discount

Major players in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

Contents of the report:
1. Executive Summary
2. Diverticulitis Disease Market Report Structure
3. Diverticulitis Disease Market Trends And Strategies
4. Diverticulitis Disease Market - Macro Economic Scenario
5. Diverticulitis Disease Market Size And Growth
…..
27. Diverticulitis Disease Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.